This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Idiopathic Pulmonary Fibrosis (IPF) Community Emphasizes The Power Of United Support For Patients During IPF World Week 2013

Stock quotes in this article: ITMN

European, American and Canadian IPF associations that are participating in IPF World Week will be posting their events on www.ipfworld.org.

About IPF Week IPF World Week aims to raise awareness of IPF around the world and bring hope to those who live with the condition.

Winning entries of 2013 'Breath of Hope' photo contest:

(Photo: http://photos.prnewswire.com/prnh/20130920/SF83164-a)(Photo: http://photos.prnewswire.com/prnh/20130920/SF83164-b)

About IPF Idiopathic pulmonary fibrosis (IPF) is an irreversible, unpredictable and ultimately fatal disease characterized by scarring (fibrosis) in the lungs, hindering the ability to process oxygen.  IPF inevitably leads to worsening lung function and exercise tolerance, and shortness of breath.  Every IPF patient follows a different and unpredictable course and it is not possible to predict if a patient will progress slowly or rapidly, or when the rate of decline may change.  Periods of transient clinical stability in IPF, should they occur, inevitably give way to continued disease progression.  The median survival time from diagnosis is two to five years, i with a five-year survival rate of approximately 20-40 percent, vi,vii which makes IPF more rapidly lethal than many cancers, including breast, ovarian and colorectal. viii,ix  IPF typically occurs in patients over the age of 45, and is more common in men than in women. iii 

About InterMune InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases. In pulmonology, we are focused on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease. Pirfenidone, the only medicine approved for IPF anywhere in the world, is marketed by InterMune in the EU and Canada as Esbriet® and is currently in a Phase 3 clinical trial to support regulatory registration in the United States. InterMune's research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. For additional information about InterMune and its R&D pipeline, please visit  www.intermune.com.

References i Meltzer EB, Noble PW.  Idiopathic pulmonary fibrosis.  Orphanet Journal of Rare Diseases. 2008; 3:8. ii EURORDIS, NORD. Idiopathic Pulmonary Fibrosis (IPF) Community. Available at: https://www.rareconnect.org/en/community/idiopathic-pulmonary-fibrosis [Last accessed: September 2013] iii Ama Fuoridalbuio. IPF World. Available at: http://www.ipfworld.org/ [Last accessed: September 2013] iv NICE clinical guideline 163: Idiopathic pulmonary fibrosis June 2013

v American Thoracic Society/European Respiratory Society. International multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2002;165:277-304.  vi Raghu G et al. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006; 174: 810-16. All others: Incidence and Prevalence Database, Timely Data Resources, Inc.

vii Cancer Facts and Figures 2009, American Cancer Society. PAH data source: Hamilton, N. and Elliot C. 13. viii Raghu G et al. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006; 174: 810-16. All others: Incidence and Prevalence Database, Timely Data Resources, Inc.

ix Cancer Facts and Figures 2009, American Cancer Society. PAH data source: Hamilton, N. and Elliot C. 13.

SOURCE InterMune, Inc.

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
2 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,804.71 -238.19 -1.40%
S&P 500 1,946.16 -26.13 -1.32%
NASDAQ 4,422.0850 -71.3050 -1.59%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs